Ambu (OTCPK:AMBF.F) - Stock Price, News & Analysis

AMBF.F Stock Overview

A medical technology company, develops, produces, and sells medical devices to hospitals, clinics, and rescue services worldwide. More details

AMBF.F fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	4/6
Past Performance	3/6
Financial Health	6/6
Dividends	0/6

Rewards

Earnings are forecast to grow 28.05% per year

Earnings grew by 39.9% over the past year

Risk Analysis

Shares are highly illiquid

Large one-off items impacting financial results

Ambu A/S Competitors

Integer Holdings

NYSE:ITGR

US$4.5b

LivaNova

NasdaqGS:LIVN

US$2.8b

CONMED

NYSE:CNMD

US$2.2b

LeMaitre Vascular

NasdaqGM:LMAT

US$2.3b

Price History & Performance

Summary of all time highs, changes and price drops for Ambu
Historical stock prices
Current Share Price	DKK 19.90
52 Week High	DKK 20.50
52 Week Low	DKK 13.03
Beta	0.79
11 Month Change	0%
3 Month Change	n/a
1 Year Change	85.98%
33 Year Change	-26.72%
5 Year Change	25.16%
Change since IPO	-54.77%

Recent updates

Shareholder Returns

	AMBF.F	US Medical Equipment	US Market
7D	0%	-1.2%	-2.1%
1Y	86.0%	22.4%	29.6%

Return vs Industry: AMBF.F exceeded the US Medical Equipment industry which returned 22.4% over the past year.

Return vs Market: AMBF.F exceeded the US Market which returned 29.6% over the past year.

Price Volatility

Is AMBF.F's price volatile compared to industry and market?
AMBF.F volatility
AMBF.F Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	8.0%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.5%
10% least volatile stocks in US Market	3.1%

Stable Share Price: AMBF.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine AMBF.F's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1937	5,196	Britt Jensen	www.ambu.com

Ambu A/S, a medical technology company, develops, produces, and sells medical devices to hospitals, clinics, and rescue services worldwide. The company offers anaesthesia, and patient monitoring and diagnostics products. The company also offers endoscopy products, such as bronchoscopes, rhinolaryngoscopes, duodenoscopes, gastroscopes, cystoscopes, and displaying units; and neurology products, including EEG and EMG electrodes, EMG guided injections, and intraoperative monitoring products.

Ambu A/S Fundamentals Summary

How do Ambu's earnings and revenue compare to its market cap?
AMBF.F fundamental statistics
Market cap	US$4.47b
Earnings (TTM)	US$33.17m
Revenue (TTM)	US$760.83m

134.8x

P/E Ratio

5.9x

P/S Ratio

Is AMBF.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AMBF.F income statement (TTM)
Revenue	DKK 5.39b
Cost of Revenue	DKK 2.19b
Gross Profit	DKK 3.20b
Other Expenses	DKK 2.97b
Earnings	DKK 235.00m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Jan 30, 2025

Earnings per share (EPS)	0.88
Gross Margin	59.38%
Net Profit Margin	4.36%
Debt/Equity Ratio	0%

How did AMBF.F perform over the long term?

See historical performance and comparison

Dividends

0.3%

Current Dividend Yield

43%

Payout Ratio

AMBF.F Stock Overview

Rewards

Risk Analysis

Ambu A/S Competitors

NYSE:ITGR

US$4.5b

NasdaqGS:LIVN

US$2.8b

NYSE:CNMD

US$2.2b

NasdaqGM:LMAT

US$2.3b

Price History & Performance

Recent News & Updates

Ambu A/S Proposes Dividend

Ambu A/S, Annual General Meeting, Dec 03, 2025

Ambu A/S to Report Q1, 2025 Results on Jan 30, 2025

Ambu A/S Maintains Earnings Guidance for the Full-Year 2023/24

Ambu A/S Elects Shacey Petrovic as Vice Chair of Board of Directors

Ambu A/S Announces Henrik Ehlers Wulff Not to Run for Re-Election for Board of Directors

Recent updates

Ambu A/S Proposes Dividend

Ambu A/S, Annual General Meeting, Dec 03, 2025

Ambu A/S to Report Q1, 2025 Results on Jan 30, 2025

Ambu A/S Maintains Earnings Guidance for the Full-Year 2023/24

Ambu A/S Elects Shacey Petrovic as Vice Chair of Board of Directors

Ambu A/S Announces Henrik Ehlers Wulff Not to Run for Re-Election for Board of Directors

Ambu A/S Provides Earnings Guidance for the Full-Year 2023/24

Ambu A/S Appoints Henrik Skak Bender as Member of the Executive Management, Effective 1 January 2024

Ambu A/S Announces Chief Financial Officer Changes

Ambu A/S to Report Q2, 2024 Results on May 14, 2024

Ambu A/S Narrows Earnings Guidance for the Full-Year 2022/23

Ambu A/S Raises Earnings Guidance for the Full-Year 2022/2023

Ambu A/S Raises Earnings Guidance for the Full-Year 2022/2023

Ambu A/S Provides Earnings Guidance for the Financial Year of 2022-2023

Ambu A/S Provides Earnings Guidance for the Financial Year of 2022-2023

Ambu A/S to Report Q3, 2023 Results on Aug 31, 2023

Ambu A/S(CPSE:AMBU B) dropped from FTSE All-World Index (USD)

Ambu A/S Reaffirms Earnings Guidance for the Full-Year 2021/2022

Ambu A/S Revises Earnings Guidance for the Full-Year 2021/2022

Ambu Announces FDA Clearance of Fifth-Generation Single-Use Bronchoscope

Ambu A/S Reaffirms Earnings Guidance for the Fiscal Year 2021/22

Ambu A/S Revises Revenue Guidance for the Fiscal 2022

Ambu Announces FDA Clearance of Single-Use Gastroscope and Next-Generation Display Unit

Ambu A/S Revises Revenue Guidance for the Fiscal 2021

Ambu A/S Reaffirms Earnings Guidance for the Fiscal Year 2021

Ambu A/S has completed a Follow-on Equity Offering in the amount of DKK 1.2345 billion.

Ambu A/S to Report Fiscal Year 2021 Results on Nov 09, 2021

Ambu A/S Announces Board Changes

Ambu A/S to Report Q2, 2021 Results on May 12, 2021